secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024193
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q3 net loss $8.7M; cash $77.2M, runway into Q1 2024; UPenn CAR-T partnership
--------------------------------------------------------------------------------

- Net loss $8.7M vs $16.2M in Q3 2021; improvement driven by non-cash warrant liability changes.
- Cash and equivalents $77.2M as of Sep 30, 2022; expected to fund operations into Q1 2024.
- R&D expenses $5.4M, G&A $3.5M; increases due to higher headcount, clinical studies, and public company costs.
- European Commission granted orphan drug designation for CAN-2409 in glioma; phase 3 protocol submitted.
- Partnered with UPenn Center for Cellular Immunotherapies to study viral immunotherapy + CAR-T in solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/0000950170-22-024193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017022024193/cadl-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer